Tim Anderson
Tim Anderson
Timothy Devon Andersonis an American professional baseball shortstop for the Chicago White Sox of Major League Baseball. Anderson played college baseball at East Central Community College, and was selected in the first round of the 2013 MLB draft by the White Sox. He made his MLB debut on June 10, 2016...
ProfessionBaseball Player
Date of Birth23 June 1993
ahead company consensus expect good guidance negative
We expect the company to put up a good show, give guidance that is ahead of consensus and not have any significant negative surprises.
beat company earnings key sale several
While the company beat earnings (expectations), sale for several key franchises lagged our estimates.
above although below company earnings expenses growth historical income interest lighter met quality rate sales tax weaker
Although the company met consensus, the quality of earnings was poor, in our view, because sales growth was weaker than we forecast, expenses were lighter than expected, interest income was above guidance, and the tax rate was significantly below historical levels.
acting companies company couple facing happen happens ironically run supposed turnaround
The company's not going out of business, but ironically it's acting like a cyclical, which drug companies aren't supposed to do. The turnaround may not happen for a couple of years, but it's a well run company that just happens to be facing a lot of problems.
bristol company concern decent drop far next patent shoe
The concern is that Bristol could be the next shoe to drop as far as patent expiration and reining in the numbers, ... But the company has a pretty decent late-stage pipeline.
bounce statement team
We just had to bounce back strong. This was a statement our team had to make.
believes hope money private sector
The private sector believes they can make money at this, and we hope they do.
difficulty raising reached stock target
The stock has reached our target of $44 and we have difficulty raising it much from here.
coming convert depends few generation next people quarters second shoes visibility
Schering will be coming out with a second generation (Claritin) drug in the next few months, so it depends how many people they convert (to the new drug), ... They could be in Merck's shoes a few quarters from now, but I don't think they have the visibility to say.
earnings growth guidance revenue seems tells
Merck tells an interesting story, yet the five-year revenue and earnings growth guidance seems far-fetched.
cancer data revenue translate
While the breast cancer data is interesting, we don't think it will translate into a significant new revenue stream.
hoping
I'm hoping they'll come out with more than they did on Jan. 20, when they weren't as forthcoming as I was hoping.
good negative people quarter time wary
The quarter was good in that they didn't have anything negative at a time when a lot of people are wary about earnings,
aware choice curious describe differ driving exceeded factors investors language performance pleased previous saying sure using
Pfizer is using curious language to describe 2006, saying 'while we are pleased that 2005 exceeded previous expectations, investors should be aware that the factors driving performance may differ materially in 2006. We are not sure what to make of this choice of words.